DNL151 clinical trials
Also written DNL151 and BIIB122.
How each study uses DNL151 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test DNL151.
- Mar 2027Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)Phase 2 · Denali Therapeutics Inc.
Studies
Open first, then newest update. How each study uses DNL151 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80CompletedPhase 2BiogenNCT05348785Written as BIIB122
- Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)Active, not recruitingPhase 2Denali Therapeutics Inc.NCT06602193Written as BIIB122 225 mg
- A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy ParticipantsCompletedPhase 1BiogenNCT06264440Written as BIIB122
- A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleTerminatedPhase 3BiogenNCT05418673Written as BIIB122
- A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian ParticipantsCompletedPhase 1BiogenNCT05229562Written as BIIB122
- Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseCompletedPhase 1BiogenNCT04056689Written as DNL151
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy VolunteersCompletedPhase 1Denali Therapeutics Inc.NCT04557800Written as DNL151
- A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male SubjectsCompletedPhase 1BiogenNCT05119790Written as [14C] BIIB122 ([14C] DNL151)
- A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy SubjectsCompletedPhase 1BiogenNCT05005338Written as BIIB122 (DNL151)
Codes
What other systems call DNL151 · ClinicalTrials.gg INT002082
- MeSH (NLM) C000730636DNL151One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730636 | DNL151 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.